LENZ THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.87 USD | -1.92% |
|
-4.02% | 0.00% |
| 04-15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
| 04-15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
16.18
USD
Average target price
36.75
USD
Spread / Average Target
+127.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 413M | |
| +3.04% | 108B | |
| +10.36% | 105B | |
| +1.57% | 23.46B | |
| -12.82% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -7.27% | 17.19B | |
| +6.12% | 13.99B | |
| +37.01% | 12.53B |
- Stock Market
- Equities
- LENZ Stock
- News LENZ Therapeutics, Inc.
- Piper Sandler Initiates LENZ Therapeutics at Overweight With $28 Price Target